Kaiserova Michaela, Chudackova Monika, Mensikova Katerina, Vastik Miroslav, Kurcova Sandra, Prikrylova Vranova Hana, Stejskal David, Kanovsky Petr
Department of Neurology, University Hospital Olomouc, I.P. Pavlova 6, 77900 Olomouc, Czech Republic.
Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, I.P. Pavlova 6, 77900 Olomouc, Czech Republic.
Brain Sci. 2021 Jan 22;11(2):141. doi: 10.3390/brainsci11020141.
Chromogranin A (CgA) and other peptides from the chromogranin-secretogranin family have been recently studied as potential biomarkers of various neurodegenerative diseases, including Parkinson's disease (PD).
We measured CgA in the cerebrospinal fluid (CSF) of 119 PD patients, 18 multiple system atrophy (MSA) patients, and 31 age-matched controls. We also correlated the values with disease duration and levodopa dose equivalent.
In the PD patients, CSF CgA tended to be lower than the control group (median 124.5 vs. 185.2 µg/L; = 0.057); however, the results did not reach statistical significance. CSF CgA levels in MSA were significantly lower compared to the control group (median 104.4 vs. 185.2; = 0.014). There was no significant difference in CSF CgA between PD and MSA patients ( = 0.372). There was no association between CSF CgA and disease duration or levodopa dose equivalent in PD or in MSA.
We observed a tendency toward lower CSF CgA levels in both PD and MSA compared to the control group; however, the difference reached statistical significance only in MSA. Based on these results, CgA may have potential as a biomarker in PD and MSA, but further studies on larger numbers of patients are needed to draw conclusions.
嗜铬粒蛋白A（CgA）以及嗜铬粒蛋白-分泌粒蛋白家族的其他肽类最近被作为包括帕金森病（PD）在内的各种神经退行性疾病的潜在生物标志物进行研究。
我们测量了119例PD患者、18例多系统萎缩（MSA）患者和31例年龄匹配的对照者脑脊液（CSF）中的CgA。我们还将这些值与疾病持续时间和左旋多巴等效剂量进行了关联分析。
在PD患者中，CSF CgA倾向于低于对照组（中位数124.5 vs. 185.2 μg/L；P = 0.057）；然而，结果未达到统计学显著性。MSA患者的CSF CgA水平与对照组相比显著降低（中位数104.4 vs. 185.2；P = 0.014）。PD和MSA患者之间的CSF CgA没有显著差异（P = 0.372）。在PD或MSA中，CSF CgA与疾病持续时间或左旋多巴等效剂量之间没有关联。
我们观察到与对照组相比，PD和MSA患者的CSF CgA水平均有降低的趋势；然而，这种差异仅在MSA中达到统计学显著性。基于这些结果，CgA可能有作为PD和MSA生物标志物的潜力，但需要对更多患者进行进一步研究才能得出结论。
